Navigation Links
Chrono Therapeutics' Smoking Cessation Technology Demonstrates Significant Reduction in Nicotine Cravings
Date:3/4/2016

CHICAGO, March 4, 2016 /PRNewswire/ -- Chrono Therapeutics, a pioneer in digital drug therapy, today announced that clinical data for the company's smoking cessation technology showed a statistically significant reduction in nicotine cravings in a trial of adult male smokers. The data were presented today at the Society for Research on Nicotine & Tobacco's 22nd Annual Meeting.

Chrono's wearable transdermal drug delivery device times nicotine delivery to when smokers have their strongest cravings. For example, 75% of all smokers reach for their first cigarette within 30 minutes of waking up. The Chrono Solution is designed to deliver the first dose of nicotine replacement therapy (NRT) shortly before a smoker wakes up and then creates a pattern of "peaks and troughs" of nicotine delivery throughout the rest of the day to assure the smoker has more nicotine support when cravings are predicted to be strongest.

"In the United States, 70 percent of smokers want to quit, but quitting is extremely difficult. In fact, most people try 8 to 10 times and this includes quit attempts with standard cessation medications like nicotine patch and gum and prescription drugs like varenicline," said Alan Levy, Ph.D., chairman and CEO of Chrono Therapeutics. "Gums and patches are designed to help manage cravings, but they are only 5 to 9 percent effective. Our goal is to solve this crisis of public health with an innovative, integrated smoking cessation solution, and the data we presented demonstrates that we are on the right path."

The clinical trial was a randomized, double blinded study of 24 adult males who smoked 11 or more cigarettes per day, indicating a high level of nicotine dependence. The subjects were divided into two groups. Test group subjects had nicotine administered over a 30-hour time period via Chrono's prototype device that delivered nicotine according to Chrono's "peaks and troughs" profile. Control subjects had a placebo solution, with no nicotine, administered at the same intervals via the same prototype device. Across both groups, subjects showed no serious adverse events or study withdrawals due to an adverse event. Skin irritation assessment showed no signs of irritation or erythema.

Cravings were assessed via three different methods: the Questionnaire for Smoking Urges (QSU), the Mood and Physical Symptoms Scale (MPSS) and a single craving question, each of which is a validated tool to assess cravings. When compared to subjects treated with placebo, test subjects had a statistically significant and clinically meaningful reduction in cravings for all assessment methods (p=0.035; p=0.034 and p=0.016, respectively).

"Achieving statistical significance in a 24-subject trial is very striking and happens infrequently in biopharma; so these results are very encouraging," noted Wende Hutton, general partner at Canaan Partners and a member of Chrono's board of directors. "Quitting smoking is one of the simplest ways to improve global public health, but as the dismal efficacy of current therapies demonstrates, it is also one of the hardest. I'm very excited to be working with a company that has the potential to solve such a serious problem." 

About Chrono Therapeutics

Effective care of the most hard-to-treat conditions requires approaches beyond simply taking medicine. Chrono's team is developing the first wearable transdermal drug delivery device that optimizes drug dosing, is embedded with sensor technology to track usage and is connected via Bluetooth to an evidence-based smartphone application that delivers real-time personalized behavioral support to keep users on track to achieve their goals. Chrono's first application is in smoking cessation, enabling smokers to overcome the world's deadliest addiction. For more information, visit www.chronothera.com.

Media Contact:
Margaux Stack-Babich
619-849-5385
margaux@canalecomm.com

 


'/>"/>
SOURCE Chrono Therapeutics
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Chrono Therapeutics Receives Second Fast Track SBIR Grant from National Cancer Institute for Patient-individualized Smoking Cessation Therapy
2. 2015 Black Book Survey Announces Drchrono as Top Ranked Mobile Electronic Health Records Application, Third Consecutive Year
3. ReelDxs medvid.io Platform Makes Asynchronous Video Telemedicine Possible In Any Medical Software
4. Chrono Therapeutics Receives Investment from Rock Health to Advance SmartStopTM Smoking Cessation Technology
5. Tobira Therapeutics Reports Fourth Quarter 2015 Financial and Year-End Business Results
6. Nektar Therapeutics to Present at Cowen and Companys 36th Annual Health Care Conference in Boston, MA
7. Cryoport Supports ImmunoCellular Therapeutics 120-Site Phase III Clinical Trial With Cold Chain Logistics
8. Immune Therapeutics, Inc., Appoints Two New Board Members
9. Spero Therapeutics Hires Cristina Larkin as Chief Commercial Officer
10. Yuhan Corporation And Sorrento Therapeutics Form Joint Venture Company - ImmuneOncia
11. Nektar Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2018)... COLLEGE PARK, Md. (PRWEB) , ... August 02, 2018 , ... ... will receive up to $7.7 million over 5 years from the National Institute of ... an ongoing tick research program to understand the immune responses of ticks that contribute ...
(Date:8/2/2018)... ... August 02, 2018 , ... Although there is a wealth of advice out ... based on a generalized “best practices” approach. But now doctors and their patients have ... optimal health. , Technology exists to help people find the right diet and personalized ...
(Date:8/2/2018)... ... 01, 2018 , ... Coral Health, a leading provider of ... that will be fuelled by the Coral Health Token. After months of intensive ... commence its token sale September 28, 2018. , Founded by a team ...
Breaking Medicine Technology:
(Date:8/11/2018)... ... ... Dr. Siavash Eftekhari, Oral and Maxillofacial Surgeon at Monarch Dental® in Grapevine, ... deliver dental care in impoverished communities. Along with a team of fellow Smile ... help deliver care to over 550 individuals in need. , This outreach was hosted ...
(Date:8/9/2018)... ... , ... Thousands of US women with FDA-approved silicone gel ... The American Society of Plastic Surgeons (ASPS), The American Society for Aesthetic Plastic ... an MRI is recommended by FDA after the first three years then every ...
(Date:8/9/2018)... (PRWEB) , ... August 09, 2018 , ... ... Jim and Kathy Coover and the company’s independent distributors, customers, and employees, the ... 24 hours of fundraising, exceeding the $2 million goal. 100 percent of the ...
(Date:8/3/2018)... ... August 03, 2018 , ... Firstaid4sport have been successfully selling ... the Firstaid4sport business in the 1990's and his son in law, Michael Davison ... providers in the UK of sports medicine products, supplying professional and amateur sports ...
(Date:8/2/2018)... ... 2018 , ... Allegheny Health Network (AHN) has ... and outside the network to vital patient imaging exams, saving valuable time and ... leading hospital systems nationwide in using lifeIMAGE, which expands access to patients’ medical ...
Breaking Medicine News(10 mins):